Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Revenue (2016 - 2025)

Amphastar Pharmaceuticals has reported Revenue over the past 13 years, most recently at $183.1 million for Q4 2025.

  • Quarterly results put Revenue at $183.1 million for Q4 2025, down 1.83% from a year ago — trailing twelve months through Dec 2025 was $719.9 million (down 1.65% YoY), and the annual figure for FY2025 was $719.9 million, down 1.65%.
  • Revenue for Q4 2025 was $183.1 million at Amphastar Pharmaceuticals, down from $191.8 million in the prior quarter.
  • Over the last five years, Revenue for AMPH hit a ceiling of $191.8 million in Q3 2025 and a floor of $101.7 million in Q2 2021.
  • Median Revenue over the past 5 years was $158.1 million (2023), compared with a mean of $151.7 million.
  • Biggest five-year swings in Revenue: surged 50.3% in 2023 and later dropped 4.38% in 2025.
  • Amphastar Pharmaceuticals' Revenue stood at $120.9 million in 2021, then grew by 11.69% to $135.0 million in 2022, then skyrocketed by 31.91% to $178.1 million in 2023, then rose by 4.73% to $186.5 million in 2024, then fell by 1.83% to $183.1 million in 2025.
  • The last three reported values for Revenue were $183.1 million (Q4 2025), $191.8 million (Q3 2025), and $174.4 million (Q2 2025) per Business Quant data.